<DOC>
	<DOCNO>NCT01487070</DOCNO>
	<brief_summary>Primary objective trial evaluate safety efficacy intravitreal injection Macugen ( pegaptanib sodium ) give least 7-14 day prior vitrectomy subject tractional retinal detachment ( withoutmacular involvement ) secondary proliferative diabetic retinopathy . Secondary objective evaluate regression neovascularization progression macular traction utilize OCT fundus photograph .</brief_summary>
	<brief_title>A Single-Center Trial Intravitreous Injections Macugen ( Pegaptanib Sodium ) Given Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<criteria>Subjects either gender age 75 year diagnose tractional retinal detachment secondary proliferative diabetic retinopathy . Subjects vitreous hemorrhage obscure posterior pole exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>